In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C

Leukemia

Volumn 17, Issue 6, 2003, Pages 999-1009

  Kindler, T ^a   Breitenbuecher, F ^a   Kasper, S ^a   Stevens, T ^a   Carius, B ^a   Gschaidemeier, H ^b   Huber, C ^a   Fischer, T ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Novartis Pharma   (Germany)

Author keywords

Apoptosis; BCR ABL; Cytosine arabinoside; Imatinib mesylate; STAT 5 tyrosine phosphorylation

Indexed keywords

BCR ABL PROTEIN; CASPASE; CYTARABINE; IMATINIB; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STAT5 PROTEIN; WORTMANNIN;

APOPTOSIS; ARTICLE; BLOOD SAMPLING; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; GEL MOBILITY SHIFT ASSAY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LEUKEMIA CELL; NICK END LABELING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UPREGULATION; WESTERN BLOTTING;

EID: 0038040669     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402940     Document Type: Article

References (53)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497.
2. Epner DE, Koeffler HP. Molecular genetics of advances in chronic myelogenous leukemia. Ann intern Med 1990; 113: 3-9.
3. Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell 1986; 27: 277-284.
4. Clark SS, McLaughlin J, Timmons M, Pendergast AM, Ben-Neria Y, Dow LW et al. Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science 1988; 238: 775-777.
5. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293.
6. Sirard C, Laneuville P, Dick JE. Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism. Blood 1994; 83: 1575-1585.
7. Skorski T, Nieborowska-Skorska M, Wlodarski P, Wasik M, Trotta R, Kanakaraj P et al. The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion and homing. Blood 1998; 91: 406-418.
8. Bedi A, Zehnbauer BA, Barberand JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994; 83: 2038-2044.
9. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG. BCR/ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 83: 1179-1187.
10. bcr/abl gene of the Philadelphia chromosome. Science 1990; 247; 824-830.
11. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature 1990; 344: 251-253.
12. Mandanas RA, Leibowitz DS, Gharehbaghi K, Tauchi T, Burgess GS, Miyazawa K et al. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells. Blood 1993; 82: 1838-1847.
13. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 1997; 16: 6151-6161.
14. Raitano AB, Halpern JR, Hambuch TM, Sawyers CL. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci USA 1995; 92: 11746-11750.
15. Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell 1992; 70: 901-910.
16. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996; 183: 811-820.
17. Ilaria Jr RL, Van Etten RA. P210 and P190 (BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996; 271; 31704-31710.
18. Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B et al. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med 1999; 189: 1229-1242.
19. Mui AL, Wakao H, O'Farrell AM, Harada N, Miyajima A. Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs. EMBO J 1995; 14: 1166-1175.
20. Wakao H, Harada N, Kitamura T, Mui AL, Miyajima A. Interleukin2 and erythropoietin activate STAT5/MGF via distinct pathways. EMBO J 1995; 14: 2527-2535.
21. Ihle JN. STAT's: signal transducers and activators of transcription. Cell 1996; 84: 331-334.
22. Moriggl R, Gouilleux-Gruart V, Jahne R, Berchthold S, Gartmann C, Liu X et al. Deletion of the carboxyl-terminal transactivation domain of MGF-Stat5 results in sustained DNA binding and a dominant negative phenotype. Mol Cell Biol 1996; 16: 5691-5700.
23. Matsumoto A, Masuhara M, Mitsui K, Yokouchi M, Ohtsubo M, Misawa H et al. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 1997; 89: 3148-3154.
24. Socolovsky M, Fallon AE, Wang S, Brugnara C, Lodish HF. Fetal anemia and apoptosis of red cell progenitors and Stat5a-/-5b/-mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 1999; 98: 181-191.
25. Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 2000; 191: 977-984.
26. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100-104.
27. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566.
28. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
29. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
30. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96: 1070-1079.
31. Haque SJ, van der Kuip H, Kumar A, Aulitzky WE, Rutherford MN, Huber C et al. Overexpression of mouse p140 subunit of replication factor C accelerates cellular proliferation. Cell Growth Differ 1996; 7: 319-326.
32. Van der Kuip H, Carius B, Haque SJ, Williams BR, Huber C, Fischer T. The DNA-binding subunit p140 of replication factor C is upregulated in cycling cells and associates with G1 phase cell cycle regulatory proteins. J Mol Med 1999; 77: 386-392.
33. Kindler T, Meyer RG, Fischer T. BCR-ABL as a target for novel therapeutic interventions. Expert Opin Ther Targets 2002; 6: 85-101.
34. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90: 3691-3698.
35. Wilson-Rawls J, Liu J, Laneuville P, Arlinghaus RB. P210 Bcr-Abl interacts with the interleukin-3 beta c subunit and constitutively activates Jak2. Leukemia 1997; 11: 428-431.
36. Rheaume E, Cohen LY, Uhlmann F, Lazure C, Alam A, Hurwitz J et al. The large subunit of replication factor C is a substrate for caspase-3 in vitro and is cleaved by a caspase-3-like protease during Fas-mediated apoptosis. EMBO J 1997; 16: 6346-6354.
37. Perry DK, Smyth MJ, Stennicke HR, Salvesen GS, Duriez P, Poirier GG et al. Zinc is a potent inhibitor of the apoptotic protease caspase-3. A novel target for zinc in the inhibition of apoptosis. J Biol Chem 1997; 272: 18530-18533.
38. Fang G, Kim CN, Perkins CL, Ramadevi N, Winton E, Wittmann S et al. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 2000; 96: 2246-2253.
39. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 2000; 96: 3195-3199.
40. Kano Y, Akuktsu M, Tsunoda S, Mano H, Sato Y, Honma Y, Furukawa Y. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001; 97: 1999-2007.
41. Frank DA, Mahajan S, Ritz J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med 1999; 5: 444-447.
42. Lionberger JM, Wilson MB, Smithgall TE. Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J Biol Chem 2000; 275: 18581-18585.
43. Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE et al. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J 2002; 21: 5766-5774.
44. Aronica SM, Broxmeyer HE. Advances in understanding the postreceptor mechanisms of action of GM-CSF, G-CSF and Steel factor. Curr Opin Hematol 1996; 3: 185-190.
45. Mangi MH, Newland AC. Interleukin-3 in hematology and oncology: current state of knowledge and future directions. Cytokines Cell Mol Ther 1999; 5: 87-95.
46. Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 2000; 95: 2118-2125.
47. Gesbert F, Griffin JD. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood 2000; 96: 2269-2276.
48. Packham G, White EL, Eischen CM, Young H, Parganas E, Ehle JN et al. Selective regulation of Bcl-XL by a Jak kinase-dependent pathway is bypassed in murine hematopoietic malignancies. Genes Dev 1998; 12: 2475-2487.
49. Neshat MS, Raitano AB, Wang HG, Reed JC, Sawyers CL. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidyl-inositol 3-kinase and Raf. Mol Cell Biol 2000; 20: 1179-1186.
50. Santos RSC, Dumon S, Mayeux P, Gisselbrecht S, Gouilleux F. Cooperation between STAT5 and phosphatidylinositol 3-kinase in the IL-3-dependent survival of a bone marrow derived cell line. Oncogene 2000; 19: 1164-1172.
51. Oetzel C, Jonuleit T, Gotz A, Van der Kuip H, Michels H, Duyster J et al. The tyrosine kinase inhibitor CGP 57148 (STI 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. Clin Cancer Res 2000; 6: 1958-1968.
52. Donato NJ, Wu JY, Zhang L, Kantarjian H, Talpaz M. Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. Blood 2001; 97: 2846-2853.
53. Yoshida K, Kharbanda S, Kufe D. Functional interaction between SHPTP1 and the Lyn tyrosine kinase in the apoptotic response to DNA damage. J Biol Chem 1999; 274: 34663-34668.